Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866316 | 1.00 | TGFBR1 (0.44) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29541562 | 1.00 | TGFBR1 (0.44) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29714329 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29530629 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29397392 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29372719 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL30674928 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29475227 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29597633 | 0.97 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1NMT2 | |
| SCHEMBL29938092 | 0.95 | TGFBR1 (0.43) | TGFBR1MMEPTGS1GSTK1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705321-A2 | SPYCATCHER ANALOGS AND USES THEREOF | Bio-Rad ABD Serotec GmbH (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20250228958-A1 | TSP1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-17 | — | — | US | claimed |
| US-12209139-B2 | N- and C-terminal tandem tag system for purification | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2025-01-28 | — | — | US | claimed |
| EP-4467561-A1 | TSP1 INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2024-11-27 | — | — | EP | claimed |
| WO-2024231728-A2 | SPYCATCHER ANALOGS AND USES THEREOF | BIO-RAD ABD SEROTEC GMBH (DE) | 2024-11-14 | — | — | WO | claimed |
| US-20240368234-A1 | SPYCATCHER ANALOGS AND USES THEREOF | BIO-RAD ABD SEROTEC GMBH (DE) | 2024-11-07 | — | — | US | claimed |
| WO-2023136342-A1 | TSP1 INHIBITOR | 第一三共株式会社 | 2023-07-20 | — | — | WO | claimed |
| WO-2026107236-A1 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST MYCOBACTERIUM TUBERCULOSIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4736889-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Yale University (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731658-A1 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES TO PREVENT OR TREAT NERVOUS SYSTEM DISEASES | Vect-Horus (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731643-A2 | COMPOSITIONS AND METHODS FOR REDUCING PAIN AND INFLAMMATION THROUGH EPIGENETIC MODULATION | Navega Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731657-A2 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES TO PREVENT OR TREAT MUSCULAR DISEASES | Vect-Horus (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4713352-A1 | CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS, CAR-MAST CELLS FORMED THEREFROM, AND METHODS OF USE THEREOF | Yale University (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2022092828-A1 | VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION | 에스케이바이오사이언스 주식회사 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022065889-A1 | VACCINE COMPOSITION COMPRISING RECOMBINANT PROTEIN FOR PREVENTION OR TREATMENT OF SARS-CORONA VIRUS-2 INFECTION | 에스케이바이오사이언스 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| EP-3971211-A1 | HIDE1 COMPOSITIONS AND METHODS | Compugen Ltd. (IL) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022056398-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION AND TREATMENT OF INFLUENZA INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220072160-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | EDITAS MEDICINE, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022047424-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3941485-A1 | ANTIGEN BINDING PROTEINS | Bio-Rad ABD Serotec GmbH (DE) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072160-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | MRE11, DCLRE1A, RAD51 | TGFBR1 3999/4885MME 3174/4885PTGS1 4166/4885 |
| US-20250228958-A1 | TSP1 INHIBITOR | ANXA11, SERPINC1, NPR1 | TGFBR1 128/4885MME 2456/4885PTGS1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.